In addition to the newsworthy headlines above, the PR Newswire team identified several trends shaping health industry news in ...

Sun Pharmaceutical Industries Ltd. closed 9.70% below its 52-week high of 1,960.20 rupees, which the company reached on ...

Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

Emrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ...

Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced financial ...

UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell ...

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an FDA-approved PD-L1 inhibitor. Japan's Ono Pharmaceutical bought an antisense ...

Indian pharmaceutical companies are aggressively expanding their US presence through a wave of acquisitions, likely as a hedge against future uncertainties. Leading players like Sun Pharma ...

Analysts expect Sun to continue to be more aggressive in chasing speciality assets, but a successful launch is necessary for the stock to gain brownie points. Sun Pharmaceutical Industries Ltd’s ...

On Tuesday, India’s top specialty generics company Sun Pharma announced the acquisition of the US-based Checkpoint for $355 million to enhance its oncology portfolio. Analysts view this ...